Jazz Pharmaceuticals plc (JAZZ)

IE — Healthcare Sector

Peers: INCY ALNY UTHR RARE APLS BMRN SGEN EXEL HALO PCVX LQDA LEGN TECH INBX PTGX DICE LRMR VRDN BPMC ASND ARGX DNLI

Automate Your Wheel Strategy on JAZZ

With Tiblio's Option Bot, you can configure your own wheel strategy including JAZZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol JAZZ
Rev/Share 66.6591
Book/Share 68.4644
PB 1.5891
Debt/Equity 1.2982
CurrentRatio 3.3762
ROIC 0.0766

MktCap 6707792000.0
FreeCF/Share 24.4087
PFCF 4.5067
PE 13.7589
Debt/Assets 0.4699
DivYield 0
ROE 0.119

Rating B+
Score 3
Recommendation Neutral
P/E Score 2
DCF Score 5
P/B Score 3
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Upgrade	JAZZ	UBS	Neutral	Buy	$145	$179	March 7, 2025
Downgrade	JAZZ	Cantor Fitzgerald	Overweight	Neutral	--	--	Feb. 26, 2025
Upgrade	JAZZ	Wells Fargo	Equal Weight	Overweight	$130	$170	Feb. 13, 2025
Upgrade	JAZZ	Morgan Stanley	Equal Weight	Overweight	$140	$175	Dec. 12, 2024

News

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

JAZZ
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

image for news Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

JAZZ
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

image for news Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics

JAZZ
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

image for news Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

JAZZ
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.

image for news Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

1
2 (current)

About Jazz Pharmaceuticals plc (JAZZ)

IPO Date 2007-06-01
Website https://www.jazzpharma.com
Industry Biotechnology
CEO Mr. Bruce C. Cozadd
Employees 2800

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.